With a robust clinical-phase pipeline, Agenus harnesses a mix of proprietary antibody platforms, which include Retrocyte Exhibit™ and SECANT®, and progressive cell therapy techniques, positioning alone to be a key contributor in the biotechnology and immunotherapy arena.Sustaining independence and editorial freedom is critical to our mission of